Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany

Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany

Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in older adults. Vaccination is effective against RSV disease and can reduce disease and economic burden.Research design and methods A static, multicohort Markov model was adapted to the German setting...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Waize, Pavo Marijic, Alen Marijam, Foteini Gkalapi, Elisa Turriani, Franziska Jakobs, Indra Jaidhauser, Dorothea Münch, Sara Pedron, Eleftherios Zarkadoulas
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Germany
health economic model
older adults
respiratory syncytial virus
RSV vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2025.2539887
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items